(ELV) Elevance Health - Ratings and Ratios
Health Plans, Health Products, Pharmacy Services, Insurance Benefits
ELV EPS (Earnings per Share)
ELV Revenue
Description: ELV Elevance Health
Elevance Health Inc (NYSE:ELV) is a leading health benefits company in the United States, operating through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The company provides a diverse range of health plans and services, including health products, administrative managed care services, and specialty insurance products.
The companys business model is diversified across various revenue streams, including individual and group health insurance, Medicare, Medicaid, and pharmacy services. Its pharmacy services business, CarelonRx, offers a range of services, including home delivery and specialty pharmacies, claims adjudication, and formulary management. Additionally, the company provides healthcare-related services, such as specialty care enablement, behavioral health, and palliative care services.
From a financial perspective, key performance indicators (KPIs) such as revenue growth, medical loss ratio (MLR), and administrative expense ratio are crucial in evaluating the companys performance. The companys ability to manage its MLR, which is the percentage of premium revenue spent on medical claims, is critical in maintaining profitability. Additionally, its administrative expense ratio, which includes costs such as salaries, marketing, and technology expenses, is also an important metric. With a market capitalization of approximately $78.6 billion, Elevance Healths financial performance is closely watched by investors.
In terms of valuation, the companys price-to-earnings (P/E) ratio of 13.53 and forward P/E ratio of 10.11 suggest that it may be undervalued relative to its earnings growth potential. Furthermore, its return on equity (RoE) of 13.94% indicates that the company is generating strong returns for its shareholders. Overall, Elevance Healths diversified business model, robust financial performance, and attractive valuation make it an interesting investment opportunity for investors.
ELV Stock Overview
| Market Cap in USD | 65,016m |
| Sector | Healthcare |
| Industry | Healthcare Plans |
| GiC Sub-Industry | Managed Health Care |
| IPO / Inception | 2001-01-02 |
ELV Stock Ratings
| Growth Rating | 4.49 |
| Fundamental | 62.8% |
| Dividend Rating | 71.0 |
| Rel. Strength | -36.1 |
| Analysts | 4.41 of 5 |
| Fair Price Momentum | 240.87 USD |
| Fair Price DCF | 208.16 USD |
ELV Dividends
| Dividend Yield 12m | 2.42% |
| Yield on Cost 5y | 3.21% |
| Annual Growth 5y | 11.40% |
| Payout Consistency | 100.0% |
| Payout Ratio | 20.2% |
ELV Growth Ratios
| Growth Correlation 3m | -84.9% |
| Growth Correlation 12m | -67.9% |
| Growth Correlation 5y | 44.6% |
| CAGR 5y | 2.36% |
| CAGR/Max DD 5y | 0.05 |
| Sharpe Ratio 12m | -0.19 |
| Alpha | -51.43 |
| Beta | 0.227 |
| Volatility | 27.11% |
| Current Volume | 2405.1k |
| Average Volume 20d | 2955.5k |
| Stop Loss | 283.1 (-3.7%) |
As of August 10, 2025, the stock is trading at USD 293.99 with a total of 2,405,100 shares traded.
Over the past week, the price has changed by +7.04%, over one month by -15.87%, over three months by -28.39% and over the past year by -43.28%.
Neither. Based on ValueRay´s Fundamental Analyses, Elevance Health is currently (August 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 62.83 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ELV is around 240.87 USD . This means that ELV is currently overvalued and has a potential downside of -18.07%.
Elevance Health has received a consensus analysts rating of 4.41. Therefore, it is recommended to buy ELV.
- Strong Buy: 13
- Buy: 5
- Hold: 4
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, ELV Elevance Health will be worth about 260.1 in August 2026. The stock is currently trading at 293.99. This means that the stock has a potential downside of -11.51%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 372.3 | 26.6% |
| Analysts Target Price | 503.5 | 71.3% |
| ValueRay Target Price | 260.1 | -11.5% |
Piotroski VR‑10 (Strict) 7.5
| Net Income (5.36b TTM) > 0 and > 6% of Revenue (6% = 11.36b TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 2.56pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 10.30% (prev 7.46%; Δ 2.84pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 6.45b > Net Income 5.36b (YES >=105%, WARN >=100%) |
| Net Debt (21.63b) to EBITDA (9.64b) ratio: 2.24 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.44 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (225.8m) change vs 12m ago -3.26% (target <= -2.0% for YES) |
| Gross Margin 54.59% (prev 28.34%; Δ 26.25pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 161.1% (prev 152.0%; Δ 9.14pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.33 (EBITDA TTM 9.64b / Interest Expense TTM 1.32b) >= 6 (WARN >= 3) |
Altman Z'' 2.95
| (A) 0.16 = (Total Current Assets 63.32b - Total Current Liabilities 43.83b) / Total Assets 121.94b |
| (B) 0.29 = Retained Earnings (Balance) 35.55b / Total Assets 121.94b |
| (C) 0.07 = EBIT TTM 8.39b / Avg Total Assets 117.46b |
| (D) 0.45 = Book Value of Equity 34.79b / Total Liabilities 78.09b |
| Total Rating: 2.95 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay Score 62.83
| 1. Piotroski 7.50pt = 2.50 |
| 2. FCF Yield 4.62% = 2.31 |
| 3. FCF Margin 2.11% = 0.35 |
| 4. Debt/Equity 0.69 = 2.27 |
| 5. Debt/Ebitda 3.13 = -1.94 |
| 6. ROIC - WACC 3.80% = 3.80 |
| 7. RoE 12.51% = 2.09 |
| 8. Rev. Trend 91.76% = 5.0 |
| 9. Rev. CAGR 7.62% = 0.95 |
| 10. EPS Trend -3.60% = -5.0 |
| 11. EPS CAGR 5.05% = 0.50 |
ELV Fundamental Data Overview
CCE Cash And Equivalents = 8.56b USD (last quarter)
P/E Trailing = 12.2551
P/E Forward = 9.6805
P/S = 0.3435
P/B = 1.487
P/EG = 0.7742
Beta = 0.612
Revenue TTM = 189.25b USD
EBIT TTM = 8.39b USD
EBITDA TTM = 9.64b USD
Long Term Debt = 28.18b USD (from longTermDebt, last quarter)
Short Term Debt = 2.01b USD (from shortTermDebt, last quarter)
Debt = 30.19b USD (Calculated: Short Term 2.01b + Long Term 28.18b)
Net Debt = 21.63b USD (from netDebt column, last quarter)
Enterprise Value = 86.64b USD (65.02b + Debt 30.19b - CCE 8.56b)
Interest Coverage Ratio = 6.33 (Ebit TTM 8.39b / Interest Expense TTM 1.32b)
FCF Yield = 4.62% (FCF TTM 4.00b / Enterprise Value 86.64b)
FCF Margin = 2.11% (FCF TTM 4.00b / Revenue TTM 189.25b)
Net Margin = 2.83% (Net Income TTM 5.36b / Revenue TTM 189.25b)
Gross Margin = 54.59% ((Revenue TTM 189.25b - Cost of Revenue TTM 85.94b) / Revenue TTM)
Tobins Q-Ratio = 2.49 (Enterprise Value 86.64b / Book Value Of Equity 34.79b)
Interest Expense / Debt = 1.13% (Interest Expense 341.0m / Debt 30.19b)
Taxrate = 24.46% (from yearly Income Tax Expense: 1.93b / 7.90b)
NOPAT = 6.34b (EBIT 8.39b * (1 - 24.46%))
Current Ratio = 1.44 (Total Current Assets 63.32b / Total Current Liabilities 43.83b)
Debt / Equity = 0.69 (Debt 30.19b / last Quarter total Stockholder Equity 43.72b)
Debt / EBITDA = 3.13 (Net Debt 21.63b / EBITDA 9.64b)
Debt / FCF = 7.54 (Debt 30.19b / FCF TTM 4.00b)
Total Stockholder Equity = 42.83b (last 4 quarters mean)
RoA = 4.40% (Net Income 5.36b, Total Assets 121.94b )
RoE = 12.51% (Net Income TTM 5.36b / Total Stockholder Equity 42.83b)
RoCE = 11.82% (Ebit 8.39b / (Equity 42.83b + L.T.Debt 28.18b))
RoIC = 8.75% (NOPAT 6.34b / Invested Capital 72.47b)
WACC = 4.95% (E(65.02b)/V(95.20b) * Re(6.85%)) + (D(30.19b)/V(95.20b) * Rd(1.13%) * (1-Tc(0.24)))
Shares Correlation 5-Years: -100.0 | Cagr: -1.66%
Discount Rate = 6.85% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 77.54% ; FCFE base≈2.73b ; Y1≈2.66b ; Y5≈2.68b
Fair Price DCF = 208.2 (DCF Value 46.87b / Shares Outstanding 225.2m; 5y FCF grow -3.53% → 2.90% )
Revenue Correlation: 91.76 | Revenue CAGR: 7.62%
Revenue Growth Correlation: 52.15%
EPS Correlation: -3.60 | EPS CAGR: 5.05%
EPS Growth Correlation: -26.04%
Additional Sources for ELV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle